DGAP-News: Medios AG: Record year 2021 and positive outlook for 2022

Press Release

Medios AG: Record year 2021 and positive outlook for 2022

• Significant increase in revenue and earnings in the 2021 financial year
• Still significant growth expected for the 2022 financial year

Berlin, March 29, 2022 - Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, today published its Annual Report 2021. Accordingly, consolidated revenue has more than doubled to 1,357.4 million (previous year 626.5 million) in the period from January to December 2021 compared to the same period of the previous year. At the same time, the operating result increased disproportionately: EBITDA pre¹ rose to 38.4 million (previous year 15.1 million), an increase of 155.3%. EBT pre¹ rose by 169.7% to 32.3 million (previous year 12.0 million). Consolidated revenue was forecasted to be between 1.2 and 1.3 billion, EBITDA pre¹ between 38.0 and 39.0 million and EBT pre¹ between 31.0 and 32.0 million.

The strong increase in revenue and earnings in the 2021 financial year is due in particular to the acquisition of Cranach Pharma GmbH and to continued organic growth.

Both operating segments record strong EBITDA pre¹ margin increase
The Pharmaceutical Supply segment achieved revenue growth of 129.4% to 1,294.5 million in the 2021 financial year (previous year 564.3 million). The main reason for the strong growth was the acquisition of Cranach Pharma and the associated supply of new customers as a result of the extension of the Medios partner network, as well as the further expansion of the product range. The segment's EBITDA pre¹ increased by 249.3% to 33.7 million (previous year 9.6 million) with an EBITDA pre¹ margin of 2.5% (previous year 1.6%). EBT pre¹ increased by 272.7% to 30.5 million (previous year 8.2 million).

The Patient-Specific Therapies segment generated revenue of 62.2 million in the 2021 financial year, slightly above the previous year's figure (previous year 61.9 million). This development is due to strategic reasons, as Medios focuses on higher-margin products in this segment, most of which have lower prices. Consequently, the segment's EBITDA pre¹ increased by 33.5% to 7.9 million (previous year 5.9 million) and EBITDA pre¹ margin from 9.0% to 10.6%. EBT pre¹ increased by 43.1% to 6.8 million (previous year 4.7 million).

Matthias Gaertner, CEO of Medios AG: "The year 2021 was a full success for us. For 2022, we continue to expect significant growth, in particular due to the NewCo Pharma Group acquired in January. Our goal is to realize synergy effects from our acquisitions, further expand our manufacturing capacities and broaden our product portfolio. In addition, we intend to continue our M&A activities in order to further improve our profit margin sustainably. Therefore, we are also considering growth opportunities abroad and the establishment of further business units in the future."

Positive outlook for the 2022 financial year
With the acquisition of the NewCo Pharma Group, Medios significantly strengthens the Patient-Specific Therapies segment and expects this to lead to a significant and sustainable increase in the profit margins of the entire Medios Group. In addition, Medios expects continued dynamic organic growth due to the high demand for Specialty Pharma drugs and the planned further innovations in the area of patient-specific therapies.

In the 2022 financial year, Medios expects revenue in the range of 1.45 - 1.60 billion. This corresponds to an increase of 6.8 - 17.9% compared to the previous year. EBITDA pre¹ is expected to be in the range of 52.0 - 58.0 million. This corresponds to an increase of 35.3 - 50.9% compared with the previous year and results in an EBITDA pre¹ margin of 3.6%.

The forecast is based on the currently existing assumption that the Ukraine conflict will not have a significant impact on the business development of Medios. In addition, the outlook takes into account potential future risks from continued high Inflation and supply bottlenecks, as well as one-off costs that will be incurred in the context of the integration of the NewCo Pharma Group and the completion and commissioning of the new laboratories in Berlin in the 2022 financial year.

Two key performance indicators for measuring the operating business success
With revenue and EBITDA pre¹, the system of key figures for managing the business success of Medios AG has comprised only two financial key figures for strategy and decision-making as well as for measuring the operating business success since January 1, 2022.

The Annual Report 2021 of Medios AG is available for download on the Investor Relations website.

¹ EBITDA is defined as consolidated earnings before interest, income taxes, depreciation and amortization. EBT is defined as net earnings before income taxes. EBITDA pre and EBT pre are each adjusted for extraordinary expenses for stock options and M&A activities. EBT pre is additionally adjusted for amortization of the customer base and goodwill.

-------------------

About Medios AG
Medios AG is the leading provider of Specialty Pharma Solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply to the manufacture of patient-specific therapies including blistering. The focus is on optimal patient care via specialized pharmacies.

Medios AG is Germany's first listed Specialty Pharma company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).

www.medios.ag

Contact
Claudia Nickolaus
Head of Investor & Public Relations, ESG Communications
Medios AG
Heidestraße 9 | 10557 Berlin | Germany
P +49 30 232 566 800
c.nickolaus@medios.ag
www.medios.ag

Anna Höffken
Consultant Investor & Public Relations
Kirchhoff Consult AG
Borselstraße 20 | 22765 Hamburg | Germany
P +49 40 609 186 34
anna.hoeffken@kirchhoff.de
www.kirchhoff.de

Disclaimer
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources.